Insider Buying: Retension Pharmaceuticals (NASDAQ:RTSN) Director Acquires 10,000 Shares of Stock

Retension Pharmaceuticals, Inc. (NASDAQ:RTSN) Director Franklin Berger bought 10,000 shares of Retension Pharmaceuticals stock in a transaction on Tuesday, October 13th. The stock was purchased at an average price of $12.00 per share, for a total transaction of $120,000.00. Following the completion of the acquisition, the director owned 10,000 shares in the company, valued at $120,000. This represents a ? increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Retension Pharmaceuticals Stock Up 2.7%

Shares of Retension Pharmaceuticals stock traded up $0.31 during mid-day trading on Tuesday, hitting $11.63. 137,519 shares of the stock were exchanged, compared to its average volume of 157,559. Retension Pharmaceuticals, Inc. has a twelve month low of $9.66 and a twelve month high of $12.50.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.